Evidence map›Paper›PMID 28581515›Full record

ArticleOncogene2017

GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.

P Shahi, C-Y Wang, J Chou, C Hagerling, H Gonzalez Velozo, A Ruderisch, Y Yu, M-D Lai, Z Werb

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

P ShahiDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
C-Y WangDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
J ChouDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
C HagerlingDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
H Gonzalez VelozoDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
A RuderischDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Y YuDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
M-D LaiDepartment of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Z WerbDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
UCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, San Francisco · USNational Cheng Kung University · TW

Funding

Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
TRANSCRIPTIONAL REGULATION OF BREAST CANCER METASTASISR01CA129523 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2008 to 2012
$2.1M
Role of GATA3 in transcriptional pathways suppressing breast cancer metastasisR01CA190851 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2015 to 2019
$2.0M
NCI NIH HHS R01 CA129523NCI NIH HHS R01 CA190851NCI NIH HHS T32 CA108462
6 · The paper itself

Abstract

Semaphorin 3B (SEMA3B) is a secreted axonal guidance molecule that is expressed during development and throughout adulthood. Recently, SEMA3B has emerged as a tumor suppressor in non-neuronal cells. Here, we show that SEMA3B is a direct target of GATA3 transcriptional activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal cell differentiation and tumor suppression. We show that GATA3 relies on SEMA3B for suppression of tumor growth. Loss of SEMA3B renders GATA3 inactive and promotes aggressive breast cancer development. Overexpression of SEMA3B in cells lacking GATA3 induces a GATA3-like phenotype and higher levels of SEMA3B are associated with better cancer patient prognosis. Moreover, SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) to abrogate breast cancer progression. Our data provide new insights into the role of SEMA3B in mammary gland and provides a new branch of GATA3 signaling that is pivotal for inhibition of breast cancer progression and metastasis.

Indexed as

AnimalsBreastBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial CellsFemaleGATA3 Transcription FactorGene Expression Regulation, NeoplasticLim KinasesMembrane GlycoproteinsMice, NudeNeoplasm MetastasisPrognosisGATA3 protein, humanGATA3 Transcription FactorLIMK1 protein, humanLIMK2 protein, humanLim KinasesMembrane GlycoproteinsSEMA3B protein, humanSemaphorinsTumor Suppressor Proteins

Identifiers

PMID28581515
PMCPMC5629104
OpenAlexW2624617162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.